FIELD: chemistry.
SUBSTANCE: invention relates to polymorphous form of compound
,
which is characterised by picture of X-ray diffraction, including discriminatory peaks approximately 7.269, 9.120, 11.038, 13.704, 14.481, 15.483, 15.870, 16.718, 17.087, 17.473, 18.224, 19.248, 19.441, 19.940, 20.441, 21.469, 21.750, 22.111, 23.319, 23.763, 24.120, 24.681, 25.754, 26.777, 28.975, 29.609, 30.073 degree 2Θ. Invention also relates to method of obtaining polymorphous form of compound (IX), which includes processing of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-ylthiazol-2-ylamino)phenyl]benzamide with methanesulfonic acid at temperature from 20 to 80°C in solvent, selected from group, which includes methanol, ethanol, acetone, diethyl ether, dioxane and their mixtures.
EFFECT: obtaining polymorphous form of compound (IX), which remains dry at 80% relative humidity and thermodynamically stable at temperatures lower than 200°C.
7 cl, 3 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | 2008 |
|
RU2456285C2 |
| SELECTIVE PROTEIN KINASE INHIBITORS | 2012 |
|
RU2612972C2 |
| USING EP4 RECEPTOR ANTAGONISTS IN TREATING IL-23-MEDIATED DISEASES | 2011 |
|
RU2571816C2 |
| 3-CYANOQUINOLIMES AS INHIBITORS OF EGF-R AND HER2 KINASES | 2002 |
|
RU2309150C2 |
| USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
| METHOD FOR SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | 2015 |
|
RU2760719C2 |
| COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION, APPLICATION OF COMPOUND OF FORMULA (I) FOR TREATMENT OF HEMATOLOGICAL AND/OR PROLIFERATIVE DISORDERS | 2016 |
|
RU2758259C2 |
| THYAZOLE DERIVATIVES, METHOD OF PRODUCTION AND APPLICATION, PHARMACEUTICAL COMPOSITION WITH PROPERTIES OF NPY RECEPTOR ANTAGONIST | 2003 |
|
RU2324685C2 |
| 1,3-DIARYL-SUBSTITUTED UREAS AS KINASE ACTIVITY MODULATORS | 2006 |
|
RU2402544C2 |
| OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2014 |
|
RU2674983C1 |
